OPTNOptiNose, Inc.

Nasdaq optinose.com


$ 0.91 $ 0.09 (10.62 %)    

Wednesday, 01-May-2024 15:59:55 EDT
QQQ $ 422.58 $ -3.07 (-0.72 %)
DIA $ 378.81 $ 0.76 (0.2 %)
SPY $ 500.35 $ -1.63 (-0.32 %)
TLT $ 88.50 $ 0.65 (0.74 %)
GLD $ 213.80 $ 1.92 (0.91 %)
$ 0.9082
$ 0.84
$ 0.00 x 0
$ 0.00 x 0
$ 0.84 - $ 0.91
$ 0.80 - $ 2.10
814,786
na
101.79M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-07-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-08-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 03-03-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-05-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 03-13-2018 12-31-2017 10-K
26 11-27-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-optinose-maintains-5-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.

Core News & Articles
Market-Moving News for April 25th
04/25/2024 12:31:16

ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% ...

 optinose-provides-corporate-updates-expects-to-produce-positive-income-from-operations-for-full-year-2025

In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31,...

 lake-street-maintains-buy-on-optinose-raises-price-target-to-4

Lake Street analyst Thomas Flaten maintains OptiNose (NASDAQ:OPTN) with a Buy and raises the price target from $3 to $4.

 hc-wainwright--co-reiterates-buy-on-optinose-maintains-5-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.

 optinose-shares-resume-trade
OptiNose Shares Resume Trade
03/15/2024 20:20:46

 hc-wainwright--co-initiates-coverage-on-optinose-with-buy-rating-announces-price-target-of-5

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on OptiNose (NASDAQ:OPTN) with a Buy rating and announce...

 optinose-q4-gaap-eps-009-inline-sales-1986m-beat-1923m-estimate

OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 47.06...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 optinoses-earnings-a-preview
OptiNose's Earnings: A Preview
03/06/2024 19:01:30

 optinose-announces-the-publication-of-reopen-phase-3-clinical-trial-program-evaluating-xhance-in-the-journal-of-allergy-and-clinical-immunology-in-practice

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusit...

 gold-moves-higher-campbell-soup-earnings-top-expectations

U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION